AnazaoHealth Corporation compounded drugs without meeting 503B conditions, including inadequate adverse event reporting.
What happened
FDA inspected the facility from September 9 to 19, 2019, and found it failed to meet section 503B conditions because its adverse event reporting procedures were inadequate. FDA also found the company compounded unapproved new drugs and misbranded drugs. The company's responses were insufficient to fully evaluate corrective actions.
What FDA found
The facility's adverse event reporting procedures did not define what an adverse event is, set reporting timelines, or require use of FDA's Safety Reporting Portal or Electronic Submission Gateway.
section 503B(b)(5) of the FDCA [21 U.S.C. § 353b(b)(5)] and 21 CFR 211.198The company compounded new drugs without FDA-approved applications.
sections 505(a) and 301(d) of the FDCA [21 U.S.C. §§ 355(a) and 331(d)]The company's drug products were misbranded because their labeling lacked adequate directions for use.
section 502(f)(1) of the FDCA [21 U.S.C. § 352(f)(1)]
What FDA wants
Within 15 working days, notify FDA in writing of the specific steps taken to address the violations, including an explanation of each step and related documentation. If the company cannot completely address the matter within that time, it must state the reason for the delay and the time within which it will do so.
Who should pay attention
- outsourcing facilities
- compounding pharmacies
- healthcare providers who use compounded drugs
This is a summary. Read the original letter on fda.gov.